Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

Immunogenicity and safety of recombinant tetravalent dengue vaccine (CYD-TDV) in individuals aged 2-45 y: Phase II randomized controlled trial in Singapore.

Leo YS, Wilder-Smith A, Archuleta S, Shek LP, Chong CY, Leong HN, Low CY, Oh ML, Bouckenooghe A, Wartel TA, Crevat D.

Hum Vaccin Immunother. 2012 Sep;8(9):1259-71. doi: 10.4161/hv.21224. Epub 2012 Aug 16.

2.

Manipulation of immunodominant dengue virus E protein epitopes reduces potential antibody-dependent enhancement.

Hughes HR, Crill WD, Chang GJ.

Virol J. 2012 Jun 18;9:115. doi: 10.1186/1743-422X-9-115.

3.

Flaviviruses and flavivirus vaccines.

Heinz FX, Stiasny K.

Vaccine. 2012 Jun 19;30(29):4301-6. doi: 10.1016/j.vaccine.2011.09.114. Review.

PMID:
22682286
4.

Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions.

de Alwis R, Smith SA, Olivarez NP, Messer WB, Huynh JP, Wahala WM, White LJ, Diamond MS, Baric RS, Crowe JE Jr, de Silva AM.

Proc Natl Acad Sci U S A. 2012 May 8;109(19):7439-44. doi: 10.1073/pnas.1200566109. Epub 2012 Apr 12.

5.

Mutation analysis of the cross-reactive epitopes of Japanese encephalitis virus envelope glycoprotein.

Chiou SS, Fan YC, Crill WD, Chang RY, Chang GJ.

J Gen Virol. 2012 Jun;93(Pt 6):1185-92. doi: 10.1099/vir.0.040238-0. Epub 2012 Feb 15.

PMID:
22337639
6.

Mechanism of dengue virus broad cross-neutralization by a monoclonal antibody.

Cockburn JJ, Navarro Sanchez ME, Fretes N, Urvoas A, Staropoli I, Kikuti CM, Coffey LL, Arenzana Seisdedos F, Bedouelle H, Rey FA.

Structure. 2012 Feb 8;20(2):303-14. doi: 10.1016/j.str.2012.01.001. Epub 2012 Jan 26.

7.

Recombinant dengue type 2 viruses with altered e protein domain III epitopes are efficiently neutralized by human immune sera.

Wahala WM, Huang C, Butrapet S, White LJ, de Silva AM.

J Virol. 2012 Apr;86(7):4019-23. doi: 10.1128/JVI.06871-11. Epub 2012 Jan 25.

8.

A West Nile virus CD4 T cell epitope improves the immunogenicity of dengue virus serotype 2 vaccines.

Hughes HR, Crill WD, Davis BS, Chang GJ.

Virology. 2012 Mar 15;424(2):129-37. doi: 10.1016/j.virol.2011.12.012. Epub 2012 Jan 14.

9.

Protection from secondary dengue virus infection in a mouse model reveals the role of serotype cross-reactive B and T cells.

Zompi S, Santich BH, Beatty PR, Harris E.

J Immunol. 2012 Jan 1;188(1):404-16. doi: 10.4049/jimmunol.1102124. Epub 2011 Nov 30.

10.

Next-generation dengue vaccines: novel strategies currently under development.

Durbin AP, Whitehead SS.

Viruses. 2011 Oct;3(10):1800-14. doi: 10.3390/v3101800. Epub 2011 Sep 26.

11.

Next generation dengue vaccines: a review of candidates in preclinical development.

Schmitz J, Roehrig J, Barrett A, Hombach J.

Vaccine. 2011 Sep 23;29(42):7276-84. doi: 10.1016/j.vaccine.2011.07.017. Epub 2011 Jul 21. Review.

PMID:
21781998
12.

From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine.

Guy B, Barrere B, Malinowski C, Saville M, Teyssou R, Lang J.

Vaccine. 2011 Sep 23;29(42):7229-41. doi: 10.1016/j.vaccine.2011.06.094. Epub 2011 Jul 13. Review.

PMID:
21745521
13.

In-depth analysis of the antibody response of individuals exposed to primary dengue virus infection.

de Alwis R, Beltramello M, Messer WB, Sukupolvi-Petty S, Wahala WM, Kraus A, Olivarez NP, Pham Q, Brien JD, Tsai WY, Wang WK, Halstead S, Kliks S, Diamond MS, Baric R, Lanzavecchia A, Sallusto F, de Silva AM.

PLoS Negl Trop Dis. 2011 Jun;5(6):e1188. doi: 10.1371/journal.pntd.0001188. Epub 2011 Jun 21. Erratum in: PLoS Negl Trop Dis. 2011 Aug;5(8). doi: 10.1371/annotation/f585335f-ff77-40ae-a8b6-ad6019af31aa. Brian, James [corrected to Brien, James D].

14.

The helical domains of the stem region of dengue virus envelope protein are involved in both virus assembly and entry.

Lin SR, Zou G, Hsieh SC, Qing M, Tsai WY, Shi PY, Wang WK.

J Virol. 2011 May;85(10):5159-71. doi: 10.1128/JVI.02099-10. Epub 2011 Mar 2.

15.

Superior neutralizing antibody response and protection in mice vaccinated with heterologous DNA prime and virus like particle boost against HPAI H5N1 virus.

Ding H, Tsai C, Gutiérrez RA, Zhou F, Buchy P, Deubel V, Zhou P.

PLoS One. 2011 Jan 28;6(1):e16563. doi: 10.1371/journal.pone.0016563.

16.

Heterologous epitope-scaffold prime:boosting immuno-focuses B cell responses to the HIV-1 gp41 2F5 neutralization determinant.

Guenaga J, Dosenovic P, Ofek G, Baker D, Schief WR, Kwong PD, Karlsson Hedestam GB, Wyatt RT.

PLoS One. 2011 Jan 26;6(1):e16074. doi: 10.1371/journal.pone.0016074.

17.

Immune response to dengue virus and prospects for a vaccine.

Murphy BR, Whitehead SS.

Annu Rev Immunol. 2011;29:587-619. doi: 10.1146/annurev-immunol-031210-101315. Review.

PMID:
21219187
18.

The necessity and quandaries of dengue vaccine development.

Thomas SJ.

J Infect Dis. 2011 Feb 1;203(3):299-303. doi: 10.1093/infdis/jiq060. No abstract available.

19.

How can vaccines against influenza and other viral diseases be made more effective?

Nara PL, Tobin GJ, Chaudhuri AR, Trujillo JD, Lin G, Cho MW, Levin SA, Ndifon W, Wingreen NS.

PLoS Biol. 2010 Dec 21;8(12):e1000571. doi: 10.1371/journal.pbio.1000571. No abstract available.

20.

Dengue: a continuing global threat.

Guzman MG, Halstead SB, Artsob H, Buchy P, Farrar J, Gubler DJ, Hunsperger E, Kroeger A, Margolis HS, Martínez E, Nathan MB, Pelegrino JL, Simmons C, Yoksan S, Peeling RW.

Nat Rev Microbiol. 2010 Dec;8(12 Suppl):S7-16. doi: 10.1038/nrmicro2460. Review.

Supplemental Content

Support Center